UK markets open in 2 hours 52 minutes

Inventiva S.A. (IVEVF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
13.640.00 (0.00%)
At close: 02:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.64
BidN/A x N/A
AskN/A x N/A
Day's range13.64 - 13.64
52-week range10.84 - 13.64
Avg. volume0
Market cap557.516M
Beta (5Y monthly)1.00
PE ratio (TTM)N/A
EPS (TTM)-1.33
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.98
  • Globe Newswire

    Update on Inventiva's cash position and on the finance documentation with the European Investment Bank

    Inventiva successfully raised approximately €14.6 million through a combination of its ATM Program for €9.3 million and new State-backed bank financing for €5.3 millionIn accordance with the terms of the credit facility announced on May 16, 2022, Inventiva entered into a warrant agreement with the European Investment Bank on July 1, 2022 Cash runway extended until the end of second quarter 2023 Daix (France), Long Island City (New York, United States), July 4, 2022 – Inventiva (Euronext Paris an

  • Globe Newswire

    Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022

    Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape by Dr. Stephen HarrisonPresentation by Dr. Michael Cooreman of three scientific abstracts from NATIVE selected for poster presentations at the EASL International Liver Congress™ 2022 Update on LEGEND, Inventiva’s Phase IIa combination study with lanifibranor and SGLT2 inhibitor empagliflozin in pati

  • Zacks

    Here's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher

    Inventiva S.A. Sponsored ADR (IVA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.